Correlation of cytokines and inducible nitric oxide synthase expression with prognostic factors in ovarian cancer

Immunology Letters

Volumn 158, Issue 1-2, 2014, Pages 195-199

  Filho, Agrimaldo Martins ^a   Jammal, Millena Prata ^a   CÔbo, Eliângela de Castro ^a   Silveira, Thales Parenti ^a   Adad, Sheila Jorge ^a   Murta, Eddie Fernando Candido ^a   Nomelini, Rosekeila Simões ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Cytokines; INOS; Ovarian cancer; Stage; Tumor grade

Indexed keywords

CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; CANCER STAGING; CARCINOGENESIS; CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; CARCINOGENESIS; CARCINOMA; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NITRIC OXIDE SYNTHASE TYPE II; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84894069001     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.01.005     Document Type: Article

References (40)

1. Marsden D.E., Friedlander M. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000, 19:11-19.
2. Murta E.F.C., Silva C.S., Gomes R.A.S., Tavares-Murta B.M., Melo A.L. Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. Eur J Gynaecol Oncol 2004, 25:707-712.
3. Narasimhan K., Changqing Z., Choolani M. Ovarian cancer proteomics: many technologies one goal. Proteomics Clin Appl 2008, 2(2):195-218.
4. Guerriero S., Ajossa S., Garau N., Piras B., Paoletti A.M., Melis G.B. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol 2005, 192:401-406.
5. Lee S., Margolin K. Cytokines in cancer immunotherapy. Cancers 2011, 3(4):3856-3893.
6. Negus R.P., Stamp G.W., Hadley J., Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997, 150:1723-1734.
7. Clerici M., Shearer G.M., Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 1998, 90(4):261-263.
8. Gajewski T.F. Cancer immunotherapy. Mol Oncol 2012, 6(2):242-250.
9. Pries R., Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006, 17:141-146.
10. Mocellin S., Bronte V., Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007, 27(3):317-352.
11. Nomelini R.S., De Abreu Ribeiro L.C., Tavares-Murta B.M., Adad S.J., Murta E.F. Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors. Mediators Inflamm 2009, 2008:186584.
12. Muntané J., la Mata M.D. Nitric oxide and cancer. World J Hepatol 2010, 2(9):337-344.
13. Hao X.P., Pretlow T.G., Rao J.S., Pretlow T.P. Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 2001, 61:419-422.
14. Murta E.F.C., Nomelini R.S. Early diagnosis and predictors of malignancy in the evaluation of adnexal mass. Curr Opin Obstet Gynecol 2006, 18:14-19.
15. Tavares Murta B.M., Cunha Fde Q., Miranda R., Adad S.J., Murta E.F. Differential tumor microenvironment in human ovarian cystic tumors. Tumori 2004, 90:491-497.
16. Pinciroli P., Alberti C., Sensi M., Canevari S., Tomassetti A. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. BMC Genomics 2013, 14:508.
17. Kassim S.K., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam Eel-D., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
18. Akahiro J., Konno R., Ito K., Okamura K., Yaegashi N. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol 2004, 9(1):42-46.
19. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother 2001, 55:111-116.
20. Merogi A.J., Marrogi A.J., Ramesh R., Robinson W.R., Fermin C.D., Freeman S.M. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997, 28(3):321-331.
21. Dobrzycka B., Terlikowski S.J., Kowalczuk O., Kinalski M. Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw 2009, 20(3):131-134.
22. Charles K.A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009, 119(10):3011-3023.
23. Hassan M.I., Kassim S.K., Saeda L., Laban M., Khalifa A. Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res 1999, 19(6C):5657-5662.
24. Nowak M., Klink M., Glowacka E., Sulowska Z., Kulig A., Szpakowski M., et al. Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol 2010, 71:97-98.
25. Zhu J., Paul W.E. CD4 T cells: fates, functions, and faults. Blood 2008, 112(5):1557-1569.
26. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4(11):e7965.
27. Tsai-Turton M., Santillan A., Lu D., Bristow R.E., Chan K.C., Shih IeM, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009, 114(1):12-17.
28. Burchill M.A., Yang J., Vang Farrar M.A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007, 114(1):1-8.
29. Waldmann T.A. The interleukin-2 receptor. J Biol Chem 1991, 266(5):2681-2684.
30. Lissoni P., Barni S., Rovelli F., Viviani S., Maestroni G.J., Conti A., et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990, 26(1):33-36.
31. Brunetti G., Bossi A., Baiardi P., Jedrychowska I., Pozzi U., Bacchella L., et al. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer 1999, 23(1):1-9.
32. Gebauer G., Rieger M., Jäger W., Lang N. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors. Anticancer Res 1999, 19(4A):2509-2511.
33. Gadducci A., Ferdeghini M., Malagnino G., Prontera C., Fanucchi A., Annicchiarico C., et al. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol Oncol 1994, 52(3):386-391.
34. Wang S., Cai G., Lu Y. Clinical implication of serum sIL-2R levels in ovarian cancer. J Tongji Med Univ 1998, 18(2):126-128.
35. Łukaszewicz M., Mroczko B., Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 2007, 117(5-6):247-251.
36. Zhou J., Ye F., Chen H., Lv W., Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 2007, 35(3):290-300.
37. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994, 54(5):1352-1354.
38. Switzer C.H., Cheng R.Y., Ridnour L.A., Glynn S.A., Ambs S., Wink D.A. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 2012, 14(5):R125.
39. Xie K., Fidler I.J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998, 17:55-75.
40. Lin W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117(5):1175-1183.